Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV-CART
2025-521571-30-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of subcuvia, amoxicillin, trimethoprim + sulfamethoxazole, levofloxacin and azithromycin in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and 1 more (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite infection outcome at 12 months. Planned start Apr 2026; status: authorised.
02
Drugs
subcuviaamoxicillintrimethoprim + sulfamethoxazolelevofloxacinazithromycin
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2025-521571-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521571-30-00.